Elagolix + Estradiol /norethindrone acetate (E2/NETA)
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Heavy Menstrual Bleeding
Conditions
Heavy Menstrual Bleeding, Uterine Fibroids
Trial Timeline
Sep 13, 2017 → Jun 28, 2024
NCT ID
NCT03271489About Elagolix + Estradiol /norethindrone acetate (E2/NETA)
Elagolix + Estradiol /norethindrone acetate (E2/NETA) is a phase 3 stage product being developed by AbbVie for Heavy Menstrual Bleeding. The current trial status is completed. This product is registered under clinical trial identifier NCT03271489. Target conditions include Heavy Menstrual Bleeding, Uterine Fibroids.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03271489 | Phase 3 | Completed |
Competing Products
3 competing products in Heavy Menstrual Bleeding
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Elagolix + 0.5 mg estradiol / 0.1 mg norethindrone acetate + 1 mg estradiol / 0.5 mg norethindrone acetate + E2/NETA placebo | AbbVie | Phase 2 | 52 |
| Elagolix + Placebo + Estradiol/Norethindrone acetate (E2/NETA) + Estradiol + Progesterone | AbbVie | Phase 2 | 52 |
| Vilaprisan (BAY1002670) | Bayer | Phase 3 | 74 |